Study identification

PURI

https://redirect.ema.europa.eu/resource/38009

EU PAS number

EUPAS30334

Study ID

38009

Official title and acronym

A Survey of Experiences and Opinions Regarding Skin Toxicities Associated with Vectibix Among mCRC Patients

DARWIN EU® study

No

Study countries

United States

Study description

This descriptive study is designed with the primary objective of assessing experiences and opinions regarding dermatologic toxicities that may develop among mCRC patients who are treated with and without Vectibix.

Study status

Finalised
Research institutions and networks

Institutions

Amgen
United States
First published:
21/02/2024
Institution

Contact details

Global Development Leader Amgen Inc.

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Amgen
Study protocol
Initial protocol
English (926.35 KB - PDF)View document
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable